

iBio, Inc.
Form 10-Q
February 14, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

Part I Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended December 31, 2010

OR

Part II Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File Number 000-53125

iBio, Inc.

(Exact name of small business registrant in its charter)

Delaware 26-2797813

*(State or other
jurisdiction of
incorporation
or
organization)*

*(I.R.S.
Employer
Identification
No.)*

**9 Innovation
Way, Suite
100, Newark,
DE**

19711

*(Address of
principal
executive
offices)*

(Zip Code)
(302) 355-0650

(Registrant's telephone number, including Area Code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Edgar Filing: iBio, Inc. - Form 10-Q

Yes ☐

No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐

No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting
company ☐

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐

No ☐

The number of shares outstanding of each of the issuer's class of common stock, as of the latest practicable date:

<i>Class</i>	<i>Outstanding at February 11, 2011</i>
Common Stock, \$0.001 par value	32,362,254 Shares

Edgar Filing: iBio, Inc. - Form 10-Q

iBio, Inc.
FORM 10-Q
For the Six Month Period Ended December 31, 2010

INDEX

	Page
<u>Part I - FINANCIAL INFORMATION</u>	
Item 1 Financial Statements (Unaudited):	
<u>Condensed Balance Sheets</u>	1
<u>Condensed Statements of Operations</u>	2
<u>Condensed Statement of Stockholders' Equity (Deficit)</u>	3
<u>Condensed Statements of Cash Flows</u>	4
<u>Notes to Condensed Financial Statements</u>	5
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3 Quantitative and Qualitative Disclosures About Market Risks	20
Item 4T Controls and Procedures	20
<u>Part II - OTHER INFORMATION</u>	
Item 1 Legal Proceedings	22
Item 1A Risk Factors	22
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3 Defaults Upon Senior Securities	23
Item 5 Other Information	23
Item 6 Exhibits	23
<u>Signatures</u>	24

Edgar Filing: iBio, Inc. - Form 10-Q

Disclosure Regarding Forward-Looking Statements

Certain statements in this Quarterly Report on Form 10-Q may constitute forward-looking statements as defined in Section 27A of the Securities Act of 1933 (the Securities Act), Section 21E of the Securities Act of 1934 (the Exchange Act), the Private Securities Litigation Reform Act of 1995 (the PSLRA) or in releases made by the Securities and Exchange Commission, all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of iBio, Inc. or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, plan , believe , expect , anticipate , intend , estimate , project , may , will , would , could , should , seeks , or scheduled to , or other similar words, or the negative of these variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the safe harbor provisions of such laws.

iBio, Inc. (the Company) cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its business described in Item 1A of the Company's Annual Report filed on Form 10-K for the year ended June 30, 2010 and in registration statements and other securities filings by the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of its forward-looking statements, which are subject to change and inherent risks and uncertainties.

The forward-looking statements contained in this Quarterly Report on Form 10-Q are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

PART I FINANCIAL INFORMATION**Item 1 FINANCIAL STATEMENTS****iBio, Inc.
Condensed Balance Sheets**

	December 31, 2010 (Unaudited)	June 30, 2010 (Note 2)
Assets		
Current assets:		
Cash	\$ 5,768,766	\$ 909,932
Accounts receivable	60,274	47,460
Prepaid expenses and other current assets	724,532	68,150
	<hr/>	<hr/>
Total current assets	6,553,572	1,025,542
Fixed assets, net	9,136	11,050
Intangible assets, net	3,853,560	3,893,653
	<hr/>	<hr/>
Total assets	\$ 10,416,268	\$ 4,930,245
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 1,970,127	\$ 2,007,166
Accrued expenses	276,100	132,865
Derivative instrument liability	5,994,703	1,714,084
	<hr/>	<hr/>
Total liabilities	8,240,930	3,854,115
	<hr/>	<hr/>
Commitments and contingencies		
Stockholders' equity (deficit):		
Preferred stock, no par value, 1,000,000 shares authorized, no shares outstanding		
Common stock, \$0.001 par value, 100,000,000 shares authorized, 32,292,254 and 28,272,655 issued and outstanding as of December 31, 2010 and June 30, 2010, respectively	36,293	28,273
Additional paid-in capital	23,186,929	14,567,349
Accumulated deficit	(21,047,884)	(13,519,492)
	<hr/>	<hr/>
Total stockholders' equity	2,175,338	1,076,130

Edgar Filing: iBio, Inc. - Form 10-Q

Total liabilities and stockholders' equity	\$	10,416,268	\$ 4,930,245

The accompanying notes are an integral part of these unaudited condensed financial statements.

iBio, Inc.
Condensed Statements of Operations
(Unaudited)

	Three months ended December 31,		Six months ended December 31,	
	2010	2009	2010	2009
Sales	\$	\$	\$	\$
Cost of goods sold				
Gross profit				
Operating expenses:				
Research and development	619,536	254,172	777,079	358,384
General and administrative	1,245,180	502,783	2,457,844	970,990
Total operating expenses	1,864,716	756,955	3,234,923	1,329,374
Operating loss	(1,864,716)	(756,955)	(3,234,923)	(1,329,374)
Other income (expense):				
Interest income	3,502	5,919	4,197	8,017
Interest expense	(12,926)		(26,051)	
Royalty income	3,506	3,824	10,204	12,954
Change in the fair value of derivative instrument liability	(2,839,227)	441,141	(4,280,619)	(541,430)
Other income (expense)	(2,845,145)	450,884	(4,292,269)	(520,459)
Loss before income taxes	(4,709,861)	(306,071)	(7,527,192)	(1,849,833)
Income tax expense	600	600	1,200	1,200
Net loss	\$ (4,710,461)	\$ (306,671)	\$ (7,528,392)	\$ (1,851,033)
Net loss per common share - Basic and diluted	\$ (0.15)	\$ (0.01)	\$ (0.25)	\$ (0.07)
Weighted average common shares outstanding - Basic and diluted	30,926,018	28,272,655	29,599,336	26,349,341

The accompanying notes are an integral part of these unaudited condensed financial statements.

iBio, Inc.
Condensed Statement of Stockholders Equity (Deficit)
(Unaudited)

	Preferred Stock		Common Stock		Additional Paid-In Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount			
Balance, June 30, 2010		\$	28,272,655	\$ 28,273	\$ 14,567,349	\$ (13,519,492)	\$ 1,076,130
Issuance of common stock and warrants for cash at \$2.00 per unit, net of expenses			4,000,000	8,000	7,227,644		7,235,644
Issuance of common stock in accordance with anti-dilution provisions of the August 2008 financing							